Business Context and Reporting Period
Company: BiomX Inc. (PHGE)
Reporting Period: Quarter ended March 31, 2025 (Q1 2025)
Business Overview: BiomX is a clinical-stage biotechnology company developing phage-based therapies to treat chronic bacterial infections, primarily focusing on Cystic Fibrosis (BX004) and Diabetic Foot Osteomyelitis (BX211). The company operates as a single segment and is headquartered in Ness Ziona, Israel. Following the acquisition of Adaptive Phage Therapeutics (APT) in March 2024, the company expanded its pipeline to include two Phase 2 assets.
Key Financial Metrics
| Metric (USD in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,659) | $(17,327) |
| Operating Loss | $(7,756) | $(6,785) |
| Research & Development Expenses | $5,250 | $4,105 |
| General & Administrative Expenses | $2,506 | $2,680 |
| Cash and Cash Equivalents (End of Period) | $20,116 | $43,007 |
| Total Cash, Cash Equivalents & Restricted Cash | $21,230 | $44,115 |
| Net Cash Used in Operating Activities | $(8,712) | $(11,356) |
| Net Cash Provided by Financing Activities | $11,913 | $38,975 |
| Accumulated Deficit | $(188,356) | $(180,297) |
| Loss Per Share (Basic & Diluted) | $(0.33) | $(2.78) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 56% to $7.7 million from $17.3 million in Q1 2024. This improvement was primarily driven by a $8.9 million swing in the fair value of warrants (from an $8.0 million loss in 2024 to a $0.9 million gain in 2025) and a significant reduction in interest expenses following the repayment of the Hercules Capital loan in March 2024.
- Operating Expenses: R&D expenses increased by 27% ($1.1 million) due to preparations for the Phase 2b trial of BX004, increased costs for the DFO trial, and higher rent post-acquisition. G&A expenses decreased by 7% ($0.2 million) largely due to the absence of acquisition-related transaction costs incurred in the prior year.
- Capital Structure: The company completed a "February 2025 Financing" (SPA) raising gross proceeds of $5.5 million and exercised existing warrants via Inducement Letter Agreements raising $6.5 million. This increased the weighted average shares outstanding significantly compared to the prior year.
- Liquidity: Total cash and restricted cash decreased from $44.1 million in Q1 2024 to $21.2 million in Q1 2025, reflecting operating burn and the timing of financing activities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash resources are estimated to fund operations only into the first quarter of 2026. Additional financing will be required to support clinical trials and operations.
- Clinical Outlook:
- BX004 (Cystic Fibrosis): A Phase 2b study is expected to initiate in Q2 2025. Results are now expected in Q1 2026 due to manufacturing delays in late 2024.
- BX211 (Diabetic Foot Osteomyelitis): Positive Phase 2 results were announced in March 2025, showing statistically significant wound healing. A Phase 2/3 trial is planned pending FDA feedback and funding.
- Geopolitical Risks: The company faces risks related to the ongoing war in Israel (Hamas/Hezbollah), which could impact operations, employee availability, and access to capital, although management states operations have not been materially impacted to date.
- Unusual Items: The financial results were significantly impacted by the accounting treatment of warrants classified as liabilities. The Q1 2025 results included a $3.3 million expense related to the repricing of warrants under Inducement Letter Agreements, offset by a $4.2 million gain from the change in fair value of warrants.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $21.2 million cash balance to fund operations through Q1 2026 and the timeline for the next capital raise.
- Warrant Liability Volatility: Assess the impact of the $5.9 million warrant liability on future earnings, as fair value changes are recorded in the income statement.
- Clinical Milestones: Monitor the initiation of the BX004 Phase 2b trial in Q2 2025 and the resolution of manufacturing delays.
- Geopolitical Exposure: Evaluate the potential for escalation in the Middle East to disrupt the Israel-based headquarters and operations.
- Dilution: Review the impact of the February 2025 financing and warrant exercises on shareholder dilution, noting the significant increase in shares outstanding.